Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024746 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
A Phase 3 study of Heart Failure, sponsored by Colorado Prevention Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
- 15
- Study locations
NCT06024746: Recruiting Phase 3 study of Heart Failure, sponsored by Colorado Prevention Center.
NCT06024746 is a Phase 3 study of Heart Failure that is actively recruiting participants, run by Colorado Prevention Center. The registered enrollment target is 1,500 participants, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (27% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06024746, a Phase 3 study of Heart Failure, is actively recruiting participants, sponsored by Colorado Prevention Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
- 15
- Study locations
Study Summary
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Primary Outcome
Hierarchical composite of the following: * Time to all-cause mortality * Number of total HF events * Time to first HF event * Difference of 5 points or greater on the Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS) assessed by the win-ratio method
Conditions Studied
Interventions
- DRUG Finerenone
- DRUG Empagliflozin
Study Locations (15)
California
- CON-10075 El Centro, CA Investigational Site - El Centro
- CON-10024 Sacramento, CA Investigational Site - Sacramento
Texas
- CON-10045 Amarillo, TX Investigational Site - Amarillo
- CON-10015 Austin, TX Investigational Site - Austin
São Paulo
- CON-21004 Braganca Paulista, Sao Paulo Investigational Site - Bragança Paulista
- CON-21049 Sao Paulo, Sao Paulo Investigational Site - São Paulo
Alabama
- CON-10004 Fairhope, AL Investigational Site - Fairhope
Georgia
- CON-10022 Atlanta, GA Investigational Site - Atlanta
Louisiana
- CON-10030 Baton Rouge, LA Investigational Site - Baton Rouge
Missouri
- CON-10002 Kansas City, MO Investigative Site - Kansas City
Goiás
- CON-21003 Goiania, Goias Investigational Site - Goiânia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What NCT06024746 shows while recruiting
NCT06024746 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Finerenone is the first listed.
NCT06024746 lists 15 locations in 12 states (California, Texas, São Paulo).
Frequently Asked Questions
What is clinical trial NCT06024746 about?
NCT06024746 is a clinical study titled "A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)". Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
What is the current status of trial NCT06024746?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2024-07-09. Estimated completion is 2026-08.
What conditions does trial NCT06024746 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06024746?
The interventions under investigation include: Finerenone (DRUG), Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT06024746?
This trial is sponsored by Colorado Prevention Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06024746 being conducted?
This trial has 15 study locations across Alabama, California, Georgia, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06024746's enrollment target sits among peer trials
1,500 54th of 397 higher than 340 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI